Roswell Park Comprehensive Cancer Center | Strategic Alliance Partners

July 14, 2020

Separate studies identify survivin as possible therapeutic target and report encouraging benefits from nintedanib.

July 07, 2020

Minimally invasive tool uses robotic technology to enable earlier, more accurate diagnosis of lung nodules.

May 12, 2020

A unique two-drug immunotherapy combination first evaluated at Roswell Park Comprehensive Cancer Center as an approach for treating some cancers will soon be available to cancer patients with COVID-19 through a clinical trial at Roswell Park.

April 22, 2020

Two Roswell Park Comprehensive Cancer Center physicians are expanding their leadership roles across the United States and abroad with recent appointments in their respective fields of specialty.

March 31, 2020

A team led by Pawel Kalinski, MD, PhD, of Roswell Park Comprehensive Cancer Center has earned a five-year, $14.54 million award from the National Cancer Institute to expand a promising immunotherapy platform.

January 20, 2020

James L. Mohler, MD, discusses the need for genetic counselors in the detection and treatment of prostate cancer.

November 13, 2019

Imaging approaches and technologies have advanced dramatically since the last such guidance was developed a decade ago, driving earlier and more effective detection and treatment.

October 31, 2019

James Mohler, MD, discusses what information should be included in a family history, based on the updated National Comprehensive Cancer Network guidelines for genetic testing in prostate cancer.

August 28, 2019

Dr. Andrew Fabiano included in Spine Society's 20 Under 40, also named an ABNS guest examiner.

April 30, 2019

Second-generation immuno-oncology studies hold great promise for breaking through the known barriers highlighted by earlier research against metastatic breast cancer.

February 01, 2019

In a pair of new studies, researchers from Roswell Park Comprehensive Cancer Center outline strategies for overcoming pancreatic cancer’s resistance to treatment through approaches that exploit this cancer’s reliance on uncontrolled, or deregulated, cell proliferation.

January 30, 2019

The National Pancreas Foundation (NPF) has designated Roswell Park Comprehensive Cancer Center as an NPF Center for pancreatic cancer.

November 24, 2018

Investigators at Roswell Park Comprehensive Cancer Center in Buffalo, New York, are working on a variety of novel approaches, including developing prophylactic drug regimens, studying methods of rejuvenating the recipient’s immune system, and analyzing genetic characteristics to improve donor selection.

May 23, 2018

Paul Mayor, MD, Gynecologic Oncology Fellow, Roswell Park Cancer Institute, discusses neuroendocrine carcinoma in gynecologic tumors.

February 20, 2018

Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses the results of the combination of crenolanib plus chemotherapy in a study of patients with acute myeloid leukemia.

February 09, 2018

Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses treatment options for patients with FLT3-mutated acute myeloid leukemia.

January 30, 2018

Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses the combination of crenolanib and cytarabine/anthracycline chemotherapy in patients with acute myeloid leukemia.

January 18, 2018

Recent advances in the understanding of the immune system are paving the way for new and effective approaches to treating cancer.

October 24, 2017

Although surgery and radiotherapy are standard treatment modalities for grade T1/T2 oral cavity cancer, both approaches have well-documented limitations, including their association with adverse effects that lower quality of life for patients.

August 21, 2017

Eunice Wang, MD, discusses the next steps for crenolanib and other emerging FLT3 inhibitors in AML.